What is the NASH resolution endpoint used in clinical trials?

The primary histological endpoint accepted by regulatory agencies for NASH trials is resolution of NASH without worsening of fibrosis — defined as a pathological assessment on liver biopsy showing an NAS (NAFLD Activity Score) component of ballooning = 0, with fibrosis stage stable or improved relative to baseline. Secondary endpoints typically include at least one stage improvement in fibrosis without worsening of NASH, and MRI-PDFF-derived hepatic fat reduction of ≥30% as an imaging surrogate.

What did the semaglutide NASH phase 2 trial show?

The Newsome et al. phase 2 trial (Lancet 2021) randomised 320 participants with NASH and liver fibrosis stage F1–F3 to semaglutide 0.1, 0.2, or 0.4 mg daily versus placebo for 72 weeks. NASH resolution without fibrosis worsening was achieved in 59% of participants on 0.4 mg versus 17% on placebo (OR 6.75) — a highly significant response. However, fibrosis improvement was not statistically significant across arms, likely reflecting the relatively short trial duration and the known slow pace of fibrosis regression.

What is SYNERGY-NASH?

SYNERGY-NASH is a phase 3 randomised controlled trial evaluating tirzepatide in participants with biopsy-confirmed NASH (now termed MASH) and liver fibrosis stages F2–F3. The primary endpoint is improvement in fibrosis stage of ≥1 without worsening of NASH. Results are anticipated in 2025–2026 and represent the most highly anticipated liver-histology dataset for the dual GIP/GLP-1 class.

Why are GLP-1/GIP agonists considered the most-studied non-statin agents in NASH?

Unlike most investigational NASH agents that target single hepatic pathways (FXR agonists, THR-beta agonists, ACC inhibitors), GLP-1 and GIP receptor agonists address multiple upstream drivers simultaneously: excess caloric intake and adiposity, hepatic steatosis via direct FFA flux reduction, hepatic inflammation via adipokine modulation, and insulin resistance — the primary driver of NASH pathogenesis. The breadth of this multi-pathway mechanism has generated more phase 2 and phase 3 NASH trial data for this class than for any other non-lipid-lowering pharmacological category.

Does tirzepatide have MRI-PDFF data in NASH populations?

Yes. Hepatic sub-studies within the SURMOUNT programme used MRI-PDFF to quantify liver fat. In the SURMOUNT-3 hepatic sub-study, tirzepatide 15 mg reduced MRI-PDFF by approximately 70% in participants with elevated hepatic fat at baseline — substantially exceeding the ≥30% reduction threshold used as a surrogate endpoint in regulatory guidance. These imaging data support SYNERGY-NASH's histological hypotheses.

NASH / MASH: Metabolic Peptide Research Evidence (UK 2026)

The condition in 60 seconds

Non-alcoholic steatohepatitis (NASH) — now increasingly termed metabolic dysfunction-associated steatohepatitis (MASH) in alignment with the 2023 international nomenclature update — is a progressive form of metabolic liver disease characterised by hepatocyte steatosis, lobular inflammation, and hepatocyte ballooning in the absence of significant alcohol consumption. It represents the inflammatory and fibrogenic end of the metabolic fatty liver disease spectrum and is the form most likely to progress to cirrhosis, hepatocellular carcinoma, and liver failure.

Prevalence estimates suggest 3–5% of the adult UK population has histologically confirmed NASH, embedded within a broader 25–30% prevalence of hepatic steatosis (NAFLD/MASLD). NASH/MASH is the most rapidly growing indication for liver transplantation in the UK and is now the leading cause of hepatocellular carcinoma in non-cirrhotic livers. The strong association with obesity, T2DM, dyslipidaemia, and the metabolic syndrome means that the metabolic peptide class directly targets the upstream aetiology of the condition.

Why metabolic peptides matter here

NASH pathogenesis is driven by excess hepatic lipid accumulation — primarily from elevated non-esterified fatty acid (NEFA) flux from dysfunctional adipose tissue, augmented by de novo hepatic lipogenesis driven by hyperinsulinaemia and dietary fructose. Hepatic inflammation follows from oxidative stress generated by the lipotoxic milieu, with activation of hepatic stellate cells producing collagen deposition (fibrosis). The key upstream driver is insulin resistance — at the adipose tissue level, in the liver, and in skeletal muscle.

GLP-1 receptor agonism addresses NASH mechanistically via at least four pathways: (1) reduction of overall adiposity, reducing NEFA flux to the liver; (2) direct hepatic GLP-1 receptor signalling, which is expressed on hepatocytes and may directly reduce lipogenesis; (3) improvement in systemic and hepatic insulin sensitivity, reducing hyperinsulinaemia-driven lipogenesis; and (4) anti-inflammatory effects mediated through adipokine modulation (adiponectin increase, TNF-alpha reduction) and potentially direct GLP-1 receptor effects on hepatic macrophages (Kupffer cells). Tirzepatide's additional GIP receptor agonism may further modify hepatic inflammation via adipose-tissue GIP receptor effects that reduce the pro-inflammatory adipokine milieu upstream of liver disease progression.

The trial landscape

Semaglutide NASH phase 2 (Newsome et al., Lancet 2021): The pivotal early-phase proof-of-concept study for GLP-1 agonism in NASH. 320 participants with biopsy-confirmed NASH (fibrosis stages F1–F3) were randomised to semaglutide 0.1 mg, 0.2 mg, or 0.4 mg daily versus placebo for 72 weeks. Histological NASH resolution (defined as NAS ballooning = 0) was achieved in 40%, 36%, and 59% of the three active dose groups respectively versus 17% with placebo. The 0.4 mg dose produced a highly significant NASH resolution finding (OR 6.75). Notably, fibrosis improvement (≥1 stage) was not statistically significantly different across arms (43% semaglutide 0.4 mg vs 33% placebo, p = 0.48), though the trial was not powered for this endpoint and the duration was likely insufficient for fibrosis regression.

MRI-PDFF hepatic sub-studies (SURMOUNT programme): Imaging sub-studies within SURMOUNT used MRI-proton density fat fraction (MRI-PDFF), the validated non-invasive hepatic fat quantification tool, to characterise tirzepatide's hepatic effects. Participants with elevated baseline hepatic fat (MRI-PDFF ≥5%) treated with tirzepatide 10 mg or 15 mg achieved reductions in hepatic fat of approximately 65–70%, exceeding the ≥30% relative reduction threshold used as a surrogate biomarker endpoint in NASH regulatory guidance. These MRI data informed the design of SYNERGY-NASH.

SYNERGY-NASH (tirzepatide, ongoing, Phase 3): The pivotal histological trial for tirzepatide in MASH, enrolling adults with biopsy-confirmed MASH and fibrosis stages F2–F3. Co-primary endpoints are (1) improvement in fibrosis of ≥1 stage without worsening of MASH activity, and (2) MASH resolution without worsening of fibrosis. Secondary endpoints include composite liver events and MRI-PDFF. Results are expected in 2025–2026 and will determine whether tirzepatide achieves the fibrosis benefit that the semaglutide phase 2 data did not have statistical power to demonstrate.

NASH phase 3 context (resmetirom): The 2024 approval of resmetirom (a THR-beta agonist) by the FDA for MASH with liver fibrosis provided the first MASH-specific regulatory precedent. Its MAESTRO-NASH phase 3 trial established the histological benchmark against which SYNERGY-NASH will be compared — fibrosis improvement in approximately 26% versus 14% placebo. Incretin trials will need to match or exceed this performance on the histological endpoint to achieve competitive positioning.

Pivotal findings

Semaglutide phase 2 NASH resolution: 59% NASH resolution at the 0.4 mg daily dose versus 17% placebo at 72 weeks (OR 6.75, 95% CI 2.94–15.5) — the strongest phase 2 NASH resolution signal of any pharmacological agent at the time of publication.
Semaglutide fibrosis (non-significant): Fibrosis improvement in 43% versus 33% (p = 0.48) — directionally favourable but underpowered, establishing that Phase 3 trials require biopsy-confirmed fibrosis improvement as a co-primary endpoint.
SURMOUNT hepatic sub-study (tirzepatide 15 mg): Approximately 70% relative reduction in MRI-PDFF hepatic fat in participants with elevated baseline steatosis — the largest imaging-based hepatic fat reduction documented for any pharmacological agent in trial data at maintenance dose.
Weight-mediated hepatic effects (SURMOUNT-1): Correlation analyses from SURMOUNT-1 suggest that the hepatic fat reduction with tirzepatide is substantially but not entirely mediated by overall weight loss, raising the question of direct hepatic GLP-1/GIP receptor effects independent of body weight trajectory.
ALT normalisation: Both semaglutide (NASH phase 2) and tirzepatide (SURMOUNT sub-studies) demonstrated alanine aminotransferase (ALT) normalisation rates substantially higher than placebo, providing a biochemical corroborate of histological hepatic improvement.

UK clinical and research positioning

No incretin-class peptide currently holds a specific MHRA licence for the treatment of NASH or MASH in the UK. Existing MHRA-licensed indications (T2DM, obesity) may include hepatically beneficial patients as a secondary consequence of treatment, and UK hepatologists increasingly consider these agents in the management of obesity-associated liver disease within their licensed parameters.

NICE has not issued a technology appraisal specific to NASH/MASH pharmacotherapy. The British Society of Gastroenterology (BSG) 2024 NAFLD guidelines acknowledge the emerging evidence base for GLP-1 receptor agonists in NASH management and recommend their use in patients with coexistent T2DM or obesity within existing licensed indications. The BSG guidance notes that a specific liver-disease licence for semaglutide or tirzepatide would require positive phase 3 histological data — which SYNERGY-NASH is designed to provide.

UK researchers studying NASH represent one of the most scientifically active communities for metabolic peptide pharmacology, given the convergence of the metabolic syndrome, T2DM, and hepatic disease in NHS cohorts. The MRI-PDFF methodology validated in incretin NASH sub-studies has been adopted as a standard imaging endpoint in UK hepatology research programmes.

Methodological caveats

NASH trials face unique methodological challenges: liver biopsy sampling variability (biopsy samples 1/50,000 of total liver volume), inter-reader variability in NAS scoring, spontaneous histological fluctuations over time, and high placebo response rates (15–20% spontaneous NASH resolution in some populations). These factors inflate sample-size requirements and create uncertainty around individual-level treatment response. The semaglutide phase 2 trial used a daily injection formulation at sub-therapeutic doses compared to the 2.4 mg weekly weight-management dose, meaning extrapolation to licensed dose-equivalents requires caution.

Frequently asked questions

What is the NASH resolution endpoint used in clinical trials?: The primary histological endpoint accepted by regulatory agencies for NASH trials is resolution of NASH without worsening of fibrosis — defined as a pathological assessment on liver biopsy showing an NAS (NAFLD Activity Score) component of ballooning = 0, with fibrosis stage stable or improved relative to baseline. Secondary endpoints typically include at least one stage improvement in fibrosis without worsening of NASH, and MRI-PDFF-derived hepatic fat reduction of ≥30% as an imaging surrogate.
What did the semaglutide NASH phase 2 trial show?: The Newsome et al. phase 2 trial (Lancet 2021) randomised 320 participants with NASH and liver fibrosis stage F1–F3 to semaglutide 0.1, 0.2, or 0.4 mg daily versus placebo for 72 weeks. NASH resolution without fibrosis worsening was achieved in 59% of participants on 0.4 mg versus 17% on placebo (OR 6.75) — a highly significant response. However, fibrosis improvement was not statistically significant across arms, likely reflecting the relatively short trial duration and the known slow pace of fibrosis regression.
What is SYNERGY-NASH?: SYNERGY-NASH is a phase 3 randomised controlled trial evaluating tirzepatide in participants with biopsy-confirmed NASH (now termed MASH) and liver fibrosis stages F2–F3. The primary endpoint is improvement in fibrosis stage of ≥1 without worsening of NASH. Results are anticipated in 2025–2026 and represent the most highly anticipated liver-histology dataset for the dual GIP/GLP-1 class.
Why are GLP-1/GIP agonists considered the most-studied non-statin agents in NASH?: Unlike most investigational NASH agents that target single hepatic pathways (FXR agonists, THR-beta agonists, ACC inhibitors), GLP-1 and GIP receptor agonists address multiple upstream drivers simultaneously: excess caloric intake and adiposity, hepatic steatosis via direct FFA flux reduction, hepatic inflammation via adipokine modulation, and insulin resistance — the primary driver of NASH pathogenesis. The breadth of this multi-pathway mechanism has generated more phase 2 and phase 3 NASH trial data for this class than for any other non-lipid-lowering pharmacological category.
Does tirzepatide have MRI-PDFF data in NASH populations?: Yes. Hepatic sub-studies within the SURMOUNT programme used MRI-PDFF to quantify liver fat. In the SURMOUNT-3 hepatic sub-study, tirzepatide 15 mg reduced MRI-PDFF by approximately 70% in participants with elevated hepatic fat at baseline — substantially exceeding the ≥30% reduction threshold used as a surrogate endpoint in regulatory guidance. These imaging data support SYNERGY-NASH's histological hypotheses.

Related peptide profiles: Semaglutide · Tirzepatide. Brand references: Ozempic · Mounjaro. Compare: Semaglutide vs Tirzepatide.